Congress wants to cut $1.5 trillion from innovative companies and threaten the loss of one million jobs in order to fund a multi-trillion-dollar spending bill, according to Pharmaceutical Research and Manufacturers of America President and CEO Stephen J. Ubl. This approach would undermine the ability to develop new treatments and jeopardize patient access to life-saving medicines.
Read More
3 Consequences of Full FDA Approval of the Pfizer Vaccine
August 23rd 2021A wave of vaccine mandates has started. The FDA's full OK today may have an effect on the unvaccinated with a wait-and-see attitude and could, according to one expert, open the door to off-label use of the vaccine by clinicians.
Read More
Encouraging Evidence-Based Healthcare with Pre-Payment Integrity
August 23rd 2021Increasing the practice of evidence-based care is vital to improving the quality and efficiency of care in the U.S. To push more providers to adopt evidence-based medicine, we must reward high-quality patient outcomes - not high volumes.
Read More
Cigna Requiring COVID-19 Vaccinations or Testing for Employees Entering U.S. Worksites
August 22nd 2021With confirmed cases of COVID-19 on the rise in the United States, Cigna has established new requirements to help protect its workforce. Employees who work remotely must be fully vaccinated before entering any U.S. worksite, beginning September 7.
Read More
Briana Contreras, associate editor of MHE, spoke with Dr. Maria Hernandez, founder and CEO of Impact4Health. Maria shared not only how healthcare inequities remain to be an issue and what needs to be addressed, but also the progress that has been made over time through awareness, conversations and laws, especially due to the heightened awareness of inequities caused from the COVID-19 pandemic and the tragic deaths of George Floyd, Breonna Taylor and many more - which have now occurred over a year ago.
Listen
In this second part of a two-part video series, Briana Contreras, associate editor of MHE caught up with MHE Editorial Advisory Board member David Calabrese, who is market president of Health Plans/PBMs at OptumRx. Calabrese shared his thoughts on the approval of the Alzheimer’s drug Aduhelm, as well as the Biden Administration's interest in putting more generics and biosimilars in the market.
Watch